Modification of Embusartan with Kojic Acid against WNT Protein for the Treatment of Breast Cancer- A Network Pharmacology and Molecular Mechanics Approach

Background: The current investigation was carried out to investigate the identified Embusartan- Kojic acid complexes as possible therapeutic options for breast cancer and to determine how well they bind to WNT protein, one of the possible targets for breast cancer that has been identified. Material and Methods: Following their creation in ChemDraw 2022 software, the reported Embusartan- Kojic acid complexes were tested according to their high-positive drug-likeness score. Compounds with high drug-likeness ratings were further predicted for their probable targets using the DIGEPPred algorithm, and STRING was used to assess the interaction between the altered proteins. The associated pathways were recorded using the KEGG pathway database. In the end, PyRx finished docking to ascertain how well the WNT protein and the Embusartan-Kojic acid complexes bound together. The ligand with the lowest binding energy score was chosen to observe the interaction between the ligand and protein. The kinematics and stability of the best proteinligand complexes were assessed using normal mode analysis in internal coordinates, which was carried out using the iMODS server. Results: Three compounds with highest drug likeness scores were identified. These substances controlled several Breast cancer-related pathways. Ultimately, two compounds with the strongest Breast cancer potentials were found using Molecular Docking, Network Pharmacology Analysis and Normal Mode Analysis. The docking sores of the two compounds, Comp 1 and Comp 2 showed to be -9.0 kcal/mol and -9.1 kcal/mol respectively with WNT protein. Conclusion: Docking analysis showed that Comp1 and Comp 2 had the strongest affinity for binding the WNT protein and all protein-ligand complexes were determined to be stable upon performing a normal mode analysis. Major Findings: With docking scores of -9.0 and -9.1 kcal/mol, two Embusartan-Kojic acid complexes, Comp 1 and Comp 2, had the greatest binding affinity to the WNT protein. Th

View article page

Download PDF